#USA #Los Angeles #Securities Fraud #Lawsuit #Capricor Therapeutics

Capricor Therapeutics Shareholders: Your Opportunity to Act

Capricor Therapeutics, Inc. (NASDAQ: CAPR) has recently come under scrutiny following allegations of securities fraud. The Law Offices of Frank R. Cruz has communicated that investors who have incurred losses connected to this company have the chance to step forward and potentially lead a class action lawsuit related to these allegations.

Background of the Case

Between December 17, 2025, and July 26, 2026, Capricor reportedly provided materially false and misleading information to its investors. Specifically, the company did not adequately disclose substantial risks related to its operations and business. It is alleged that amidst this timeframe, Capricor made important changes to its statistical analysis plan aimed at evaluating clinical data for its product, Deramiocel, intended for treating Duchenne muscular dystrophy.

Furthermore, it is claimed that the U.S. Food and Drug Administration (FDA) had not approved these changes before the company submitted its Biologics License Application (BLA) for Deramiocel. This omission poses significant questions about the credibility of the clinical results as it raises the possibility that the FDA might not see sufficient evidence demonstrating the effectiveness of Deramiocel. As a result, the chances of receiving regulatory approval for this treatment could be substantially impacted.

Why Investors Should Act

The allegations suggest that Capricor's management offered overly optimistic portrayals of the company's business prospects and operations. These representations may have led investors to make decisions based on misleading information, ultimately resulting in financial losses. The Law Offices of Frank R. Cruz is urging impacted stakeholders to consider joining the lawsuit before the lead plaintiff deadline of September 28, 2026.

If you are an investor affected by this situation, you have the opportunity to become actively involved in seeking justice for losses incurred. Being a lead plaintiff can provide a platform for holding Capricor accountable for alleged deceptive practices, which may foster an environment for improved transparency in corporate governance moving forward.

Involvement and Next Steps

To participate or gather more details about the class action lawsuit against Capricor, affected investors are encouraged to contact the Law Offices of Frank R. Cruz directly. You do not need to take immediate action to be a class member, as you may retain representation of your choice while deciding on your approach. For those interested, you can reach out via email or phone, as indicated in the firm's announcement.

This scenario serves as a cautionary tale on the importance of ensuring that publicly-traded companies present accurate and complete information to their investors. As the legal process unfolds, close attention should be paid to developments surrounding Capricor Therapeutics, as many investors are left with concerns about the transparency and reliability of information provided by corporate entities.

In conclusion, if you are a shareholder of Capricor Therapeutics and have experienced financial losses, now is your chance to explore potential legal avenues to seek restitution for those losses. Stay informed and proactive as this story develops, it could have significant implications not only for your investments but also for the broader market landscape.

For any inquiries or if you're ready to take action, feel free to reach out to Frank R. Cruz Law Offices for expert guidance on how best to navigate this situation.